Dompé - Este...5 ©2019 Dompé farmaceutici S.p.A All rights reserved. Confidential and...

DompéIl futuro è già presente

2

©2019 Dompé farmaceutici S.p.A All rights reserved. Confidential and proprietary.

WHO WE AREDompé at a glance

3


Production recognized for its quality and efficiency at international level

MILLION PACKAGES OF DRUGS MARKETED IN ABOUT 40 COUNTRIES60

Established in Milan in 1940s, Dompé is an Italian biopharmaceutical company

300MILLION $2018 REVENUES

The value of our network

PARTNERSHIPWITH LEADING GLOBAL BIOTECH AND PHARMA COMPANIES AT INTERNATIONAL LEVEL

R&D investments on turnover

15%*

*2018 data

People

800

4


The value of strategic partnership in biotech field

5


Research is at the centre of Dompé strategy

Production site and Research & Development

250 EMPLOYEES

70RESEARCHERS

of which

Watch the video of our L’Aquila Plant here: https://youtu.be/lHvnWT5qX9g

L’Aquila

https://youtu.be/lHvnWT5qX9g

6


Dompé markets

7


Leadership in Italy in the Primary Care market

A business based on two pillars

Breakthrough innovation - Biotech

• Neurotrophic Keratitis

• Hypertension

Incremental innovation - Primary Care

• Pain and Inflammation• Respiratory Diseases• Gastroenterology• Cardiology• Pediatric • Sport and Wellness

A commitment to market innovative therapeutic solutions worldwide

8


RESEARCH & DEVELOPMENT

9


NETWORKCOMPLEXITY MANAGEMENT

OF EXCELLENCE

FOCUSUNMET MEDICAL NEEDS

ON HIGH UNMET MEDICAL NEEDS IN

RARE DISEASES AND SPECIALTIES

R&DBREAKTHROUGH INNOVATION

Dompé strategic choices

10


10

WORKING TO DISCOVER INNOVATIVE TREATMENTS

FOR PATIENTS WORLDWIDE

The pillars of our breakthrough innovation

TRANSPLANTS DIABETESOPHTHALMOLOGY ONCOLOGY

11


11

STUDIES13

PRIMARYCARE

ONCOLOGY

Data 2018

DIABETES &TRANPLANTS

OFTALMOLOGY

5STUDIES

CENTRES59 CENTRES21

4STUDIES 5STUDIES

CENTRES77 CENTRES33

2000PATIENTS

WORLDWIDE

Our clinical trials

12


rhNGF (cenegermin): an all-round commitment in eye care

The Nerve Growth Factor (NGF) is a

naturally occurring protein in man,

discovered by the Nobel prize winner

Rita Levi Montalcini

NGF is involved in differentiation, growth, maintenance and survival of neurons

rhNGF was developed at the R&D centre in L’Aquila and is currently studied in patients with rare eye diseases…

Neurotrophic Keratitis

and with common conditions, like Dry Eye Disease

OPHTHALMOLOGY

13


Il viaggio del farmaco: il nostro caso… di successo

Luoghi dell’innovazione

Technology Transfer

Regolatorio(Agenzie)

Accesso(Istituzioni)

Rita Levi Montalcini

Anabasis

Anni ‘50 Pubblicazione sul NEJM

1998

Dal 2012 al 2017più di 10 incontri

con EMA

Sviluppo(Azienda)

Clinical trials Int.2012 - 2017

PAZIENTE

EC AuthorizationLuglio 2017

Germania: Nov 2017Italia: Gen 2018

USA: 2018

14


Breakthrough Innovation: FDA approval

15


August 2018: FDA approval

16


The approval is special in that it marks three firsts in the U.S. drug history:

• After winning orphan drug and priority review designations, Oxervate on

Wednesday became the first FDA-approved drug for NK

• Oxervate is the first application of a human NGF as drug

• As an eye drop, Oxervate is the first topical biologic approved in ophthalmology

17


Un altro esempio di network innovation:

18


Dompé Drug Discovery Platform – EXSCALTE

Il consorzio Antarex

Università

IndustriaCentri di

supercalcolo

19

Il consorzio Antarex è il frutto del lavoro di una rete di soggettipubblici e privati per creare una piattaforma di screening virtuale.


HPC-accelerated Drug Discovery System

Exscalate è una piattaforma di supercalcolo dotata di una “biblioteca chimica” di oltre 500 miliardi di molecole.

Può valutare contemporaneamente più di 3 milioni di molecole al secondo su 30 target biologici.

Dompé - Este...5 ©2019 Dompé farmaceutici S.p.A All rights reserved. Confidential and...

Documents

Transcript of Dompé - Este...5 ©2019 Dompé farmaceutici S.p.A All rights reserved. Confidential and...